NCT04182503

Brief Summary

The Environmental Factors and Embryonic Development Project was set up to investigate environmental exposures and behavioral factors responsible for embryonic dysplasia and gestational complications in pregnant women.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2019

Typical duration for all trials

Geographic Reach
1 country

19 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 12, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 12, 2019

Completed
20 days until next milestone

First Posted

Study publicly available on registry

December 2, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

December 2, 2019

Status Verified

November 1, 2019

Enrollment Period

2.4 years

First QC Date

November 12, 2019

Last Update Submit

November 28, 2019

Conditions

Outcome Measures

Primary Outcomes (9)

  • Incidence of spontaneous abortion

    up to 28 gestational weeks

  • Incidence of fetal death/stillbirth

    after 20 gestational weeks to delivery

  • Incidence of birth defects

    Delivery

  • Incidence of low birth weight

    Delivery

  • Incidence of preterm birth

    Delivery

  • Incidence of pregnancy with heart disease

    During pregnancy (up to 10 months)

  • Incidence of pregnancy with hyperthyroidism

    During pregnancy (up to 10 months)

  • Incidence of gestational diabetes

    During pregnancy (up to 10 months)

  • Incidence of gestational hypertension

    During pregnancy (up to 10 months)

Study Arms (16)

Beijing

Other: No intervention

Guangzhou

Other: No intervention

Jinan

Other: No intervention

Nanjing

Other: No intervention

Hangzhou

Other: No intervention

Wuhan

Other: No intervention

Zunyi

Other: No intervention

Xiangyang

Other: No intervention

Nantong

Other: No intervention

Suizhou

Other: No intervention

Huangshi

Other: No intervention

Changzhou

Other: No intervention

Suqian

Other: No intervention

Shiyan

Other: No intervention

Xiaogan

Other: No intervention

Huanggang

Other: No intervention

Interventions

This is a multi-city observational cohort study without intervention.

BeijingChangzhouGuangzhouHangzhouHuanggangHuangshiJinanNanjingNantongShiyanSuizhouSuqianWuhanXiangyangXiaoganZunyi

Eligibility Criteria

Age20 Years - 45 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant women attending their first routine antenatal examinations.

You may qualify if:

  • pregnancy within 13 weeks;
  • age between 20-45 years;
  • natural conception;
  • singleton pregnancy;
  • living in the local area for one year or more.

You may not qualify if:

  • pregnant women with serious chronic diseases and infectious diseases (such as cancer, chronic cardiovascular and cerebrovascular diseases, chronic renal failure, HIV infection);
  • have participated in other scientific research projects;
  • refuse to participate or are unwilling to sign informed consent.;
  • are unable to guarantee delivery in our designated hospitals.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Haidian Maternal and Child Healthcare Hospital

Beijing, Beijing Municipality, China

RECRUITING

Guangdong General Hospital

Guangzhou, Guangdong, China

ACTIVE NOT RECRUITING

Meitan People's Hospital

Zunyi, Guizhou, China

ACTIVE NOT RECRUITING

Renhuai Hospital of Traditional Chinese Medicine

Zunyi, Guizhou, China

ACTIVE NOT RECRUITING

The First Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China

ACTIVE NOT RECRUITING

The Second Affliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China

ACTIVE NOT RECRUITING

People's Hospital of Qichun County

Huanggang, Hubei, China

ACTIVE NOT RECRUITING

Huangshi Maternal and Child Healthcare Hospital

Huangshi, Hubei, China

ACTIVE NOT RECRUITING

Shiyan Maternal and Child Healthcare Hospital

Shiyan, Hubei, China

ACTIVE NOT RECRUITING

Maternal and Child Healthcare and Family Planning Service Center of Zengdu District

Suizhou, Hubei, China

ACTIVE NOT RECRUITING

Huangpi Maternal and Child Healthcare Hospital

Wuhan, Hubei, China

ACTIVE NOT RECRUITING

Maternal and Child Healthcare Hospital of HuBei

Wuhan, Hubei, China

ACTIVE NOT RECRUITING

Xiangyang No. 1 People's Hospital, Hubei University of Medicine

Xiangyang, Hubei, China

ACTIVE NOT RECRUITING

Anlu Maternal and Child healthcare Hospital

Xiaogan, Hubei, China

ACTIVE NOT RECRUITING

Changzhou Second People's Hospital

Changzhou, Jiangsu, China

ACTIVE NOT RECRUITING

Nantong Maternal and Child Healthcare Hospital

Nantong, Jiangsu, China

ACTIVE NOT RECRUITING

Shuyang Hospital Affiliated to Xuzhou Medical University

Suqian, Jiangsu, China

ACTIVE NOT RECRUITING

Center for Reproductive Medicine, Shandong University

Jinan, Shandong, China

ACTIVE NOT RECRUITING

Women's Hospital, School of Medicine, Zhejiang University

Hanzhou, Zhejiang, China

ACTIVE NOT RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

The investigators will collect a 8 ml blood sample and a 10 ml urine sample from each pregnant woman at their first pregnancy examination, and a 10 ml cord blood sample at delivery. The blood sample will be separated into plasma/serum and white blood cells/blood clots shortly after collection and then stored at -80 degrees celsius. The urine sample will be separated into several tubes before storage at -80 degrees celsius.

MeSH Terms

Conditions

Abortion, SpontaneousFetal DeathStillbirthCongenital AbnormalitiesPremature BirthDiabetes, GestationalHypertension, Pregnancy-Induced

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDeathPathologic ProcessesPathological Conditions, Signs and SymptomsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesObstetric Labor, PrematureObstetric Labor ComplicationsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Officials

  • Xuejun Shang, PhD

    Jinling Hospital, China

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Xuejun Shang, PhD

CONTACT

Song Xu, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 12, 2019

First Posted

December 2, 2019

Study Start

August 12, 2019

Primary Completion

December 31, 2021

Study Completion

December 31, 2022

Last Updated

December 2, 2019

Record last verified: 2019-11

Locations